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Background Clinical practice guidelines (CPGs) play a critical role in standardizing
and improving treatment outcomes based on the available evidence. It is unclear
how many CPGs are available globally to assist clinicians in the management of
patients with skin disease.
Objectives To search for and identify CPGs for dermatological conditions with the
highest burden globally.
Methods We adapted a list of 12 dermatological conditions with the highest bur-
den from the Global Burden of Disease (GBD) study 2019. A systematic literature
search was done to identify CPGs published between October 2014 to October
2019. The scoping review was conducted and reported in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
framework.
Results A total of 226 CPGs were included. Melanoma had the greatest representa-
tion in the CPGs, followed by dermatitis and psoriasis. Skin cancers had a rela-
tively high CPG representation but with lower GBD disease burden ranking.
There was an uneven distribution by geographical region, with resource-poor
settings being under-represented. The skin disease categories of the CPGs corre-
lated weakly with the GBD disability-adjusted life-years metrics. Eighty-nine CPGs
did not have funding disclosures and 34 CPGs were behind a paywall.
Conclusions The global production of dermatology CPGs showed wide variation in
geographical representation, article accessibility and reporting of funding. The
number of skin disease CPGs were not commensurate with its disease burden.
Future work will critically appraise the methodology and quality of dermatology
CPGs and lead to the production of an accessible online resource summarizing
these findings.
What is already known about this topic?
• Skin-related diseases are leading causes of disability and disease burden globally.
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• Clinical practice guidelines (CPGs) are important to ensure appropriate standards of
care for skin conditions.
• The number, distribution, accessibility and quality of dermatological CPGs available
globally is unknown.
What does this study add?
• This is the first scoping review to describe the distribution of CPGs for common
dermatological conditions of highest burden available internationally.
• Inflammatory skin conditions and skin cancers represent a higher proportion of the
number of CPGs produced, largely driven by high-income countries.
• Further studies to evaluate the quality of CPGs in dermatology, and the develop-
ment of CPGs in skin diseases predominantly affecting resource-poor countries, are
needed.
Clinical practice guidelines (CPGs) are defined as statements
that include recommendations intended to optimize patient
care that are informed by a systematic review of evidence and
an assessment of the benefits and harms of alternative care
options.1 CPGs have the potential to improve healthcare qual-
ity by synthesizing and translating evidence into recommenda-
tions; identifying appropriate evidence-to-practice gaps;
decreasing costly and preventable adverse events; optimizing
patient outcomes; and facilitating shared decision-making pro-
cesses.2,3 The production of CPGs is a resource-intensive pro-
cess. Research waste is a problem in the biomedical setting,4
with poor design, conduct and reporting of medical research
being a common problem for the production of CPGs in der-
matology.4,5
There are few resources available that comprehensively doc-
ument the number and quality of CPGs worldwide, and none
dedicated to dermatological diseases. We previously conducted
a survey of the BJD readership about CPGs and found that a
key concern was how CPGs were accessed, with many readers
suggesting that an online comprehensive dermatology guide-
line repository would be helpful for quick access and refer-
ence in the clinic.6
Therefore, there is a need to collate CPGs in common der-
matological diseases available internationally.7 Firstly, this may
help reduce research waste and identify high-quality CPGs and
systematic reviews for future guideline development groups
(GDGs) to reference from, avoiding duplication of work. Sec-
ondly, it will provide patients and clinicians with a summary
of critically appraised dermatology CPGs, also highlighting
areas for improvement in CPG reporting and development
standards. Thirdly, a resource that clinicians, including those
from resource-poor countries, can freely access from any-
where in the world would serve as an important contribution
for education and reference purposes in dermatology.
With this mind, we performed a global scoping review as a
first step to collate and describe the state of current CPGs within
the field of dermatology. The review questions were: (i) How
many CPGs are produced for the dermatological conditions of
the highest burden globally in a period of 5 years? and (ii) Is
the number of internationally available clinical guidelines on
skin diseases commensurate with their disease burden?
Materials and methods
We performed a systematic search for CPGs of common skin
conditions following a prespecified protocol in accordance
with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement,8 focusing on the skin con-
ditions with the highest burden adapted from the Global Bur-
den of Disease (GBD) Study 2019:9,10 acne, alopecia areata,
atopic and contact dermatitis, cellulitis, keratinocyte carci-
noma, cutaneous malignant melanoma, psoriasis, scabies, urti-
caria, tinea capitis, venous ulcers, viral warts and molluscum
contagiosum. All records were screened by at least two inde-
pendent appraisers. Disagreements at any stage were recon-
ciled by discussion with a third appraiser.
Searches were performed in MEDLINE, Embase, National
Institute for Health and Care Excellence (NICE) Evidence Search,
Guidelines International Network, ECRI Guidelines Trust, Aus-
tralian Clinical Practice Guidelines, Trip Medical Database and
DynaMed. Appropriate disease search terms were combined
with a guidelines search filter from the Canadian Agency for
Drugs and Technologies in Health. Our full search strategy is
provided in Appendix S1 (see Supporting Information). The
search was conducted in October 2019 and we included CPGs
published between October 2014 and October 2019.
We supplemented the online search with manual searches
for guidelines produced by dermatological societies listed
under the International League for Dermatological Societies.
We also contacted CPG-producing dermatological societies
directly to solicit copies of their current guidelines. Where we
did not receive a response, we searched for CPGs produced by
the dermatology societies through Google and the society
websites.
To capture the full range of guidelines, we used a broad
definition of CPGs, inclusive of consensus agreement
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guidelines informed by reviews of the evidence that were sys-
tematic or structured, developed by local, regional, national or
international groups or affiliated governmental organizations.
All CPGs involving the diagnosis, screening, management,
treatment and prevention of the included skin conditions were
eligible. Records that lacked systematic search protocols or
explicit criteria for appraising evidence, secondary publications
derived from CPGs, conferences or consensus statements based
on the opinion of expert panels, editorials, clinical trials and
single-author documents were excluded. Following discussion
with the study group, we excluded CPGs that were directed
predominantly for policymakers, such as health technology
assessments, and those that focused on treatment-related side-
effects. If multiple or updated versions of the same guideline
and organization were found, we selected the latest full or
long version, and subsequently the English version, which was
often used in peer-reviewed publications. We included guide-
lines from any country and in any language; Google Translate
was used to translate the abstracts and full-text records of
non-English CPGs, with the exception of Thai CPGs, where a
translator was used. The inclusion and exclusion criteria can
be found in Appendix S2 (see Supporting Information).
The titles and abstracts were screened using the website and
the application ‘Rayyan’.11 If no abstract was available, full-
text articles were obtained and screened in order to be consid-
ered for inclusion. In addition, CPG repositories from mem-
bers of the International League of Dermatological Societies,
Guidelines International Network, Dynamed, NICE and Trip
were hand-searched to identify additional relevant CPGs. We
extracted the following items from the full-text records for
analysis: skin disease subtypes; organization producing the
CPG; year of publication; geographical region; language; key-
word in title; topics covered; publication source; funding
source; and whether the CPG was behind a paywall. We also
evaluated the distribution of CPGs by sociodemographic index
(SDI), an indicator of a location’s sociodemographic develop-
ment, based on the country and geographical region where
the CPGs were produced.10 The SDI, which combines infor-
mation on income per capita, education and fertility, was used
to categorize all GBD geographies into five SDI quintiles (high,
high–medium, medium, low–medium and low). We further
calculated the correlation between the number of CPGs pub-
lished for each skin disease to the GBD 2019 disability-
adjusted life-years (DALYs) estimates.
We registered our study protocol with OSF registries (https://
osf.io/fuj3h) on 30 October 2019. Data were collected, summa-
rized and tabulated in a standardized Excel spreadsheet (Micro-
soft, Redmond, WA, USA) for descriptive analysis.
Results
Identification and selection of clinical practice guidelines
The PRISMA flowchart of the guideline selection is summa-
rized in Figure 1. Our search yielded 17 211 potential cita-
tions. After duplicates were removed, 14 914 were screened
by title and abstract. Of the 576 full-text articles screened,
137 CPGs met the inclusion criteria. In addition, a further 89
articles were identified through manual searching and local
dermatological society websites. In total, 226 CPGs were
included in the final analysis. A list of the included articles
and detailed summary at full-text screening stage are provided
in Table S1 (see Supporting Information).
Trends in dermatological clinical practice guidelines
The included CPGs were published between October 2014
and October 2019. Across the 12 skin diseases, the top-five
number of CPGs produced were melanoma (n = 41), atopic
dermatitis (n = 30) and contact dermatitis (n = 12), psoriasis
(n = 29), venous ulcer (n = 25) and urticaria (n = 24) (Fig-
ure 2). Melanoma comprised 15% (n = 7/46) of dermatologi-
cal CPGs in 2015, with a steady rise over 5 years to 22%
(n = 12/54) in 2019. Venous ulcer was one of the most
prevalent (15%; n = 7/46) dermatological CPGs in 2015 but
dropped to 6% (n = 3/54) in 2019. The frequency of atopic
and contact dermatitis, psoriasis and urticaria CPGs trended
upwards from 2014 to 2019. The apparent increase in CPGs
could, in part, be explained by the fact that only the latest
version of any CPG was included in the database. Overall,
there was a low representation for cellulitis (n = 7), scabies
(n = 5), viral warts and molluscum contagiosum (n = 4),
alopecia areata (n = 3) and tinea capitis (n = 1).
Characteristics of dermatological clinical practice
guidelines
The top-three journals publishing the highest frequencies of
dermatology CPGs were the Journal of the European Academy of Der-
matology and Venereology (n = 11), the Journal of the American Academy
of Dermatology (n = 9) and the British Journal of Dermatology
(n = 8). Skin disease CPGs were published in dermatology
journals (n = 89; 394%) and in nondermatology journals
(323%; n = 73), and some were available online only
(283%; n = 64). The majority (531%; n = 120) of skin dis-
ease CPGs were multidisciplinary collaborative efforts between
different specialties, with a significant minority (372%;
n = 84) solely written by GDGs from the dermatology com-
munity. For example, there was involvement of paediatricians
and allergists in atopic dermatitis CPGs, whereas for melanoma
and keratinocytes carcinomas CPGs often consisted of a multi-
disciplinary team of dermatologists, surgeons, oncologists and
pathologists. We also found that 881% (n = 199) of CPGs
were developed by national or regional GDG members, while
119% (n = 27) were part of a collaborative effort consisting
of internationally recognized experts.
The majority (721%; n = 163) of dermatological CPGs
were developed by countries with a high SDI vs. high–middle
(80%; n = 18), middle- (53%; n = 12) and low-SDI coun-
tries (18%; n = 4). The geographical distribution included
Europe (518%; n = 117), North America (212%; n = 48),
Asia (155%; n = 35), Latin America (49%; n = 11) and
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Australasia (44%; n = 10), as well as international collabora-
tion across these regions (22%; n = 5) (Figure 3). The coun-
tries with the highest number of dermatological CPGs are the
USA (150%; n = 34) and the UK (106%; n = 24), together
representing about 25% of all CPGs. The majority of dermato-
logical CPGs were written or available in English (765%;
n = 173), whereas some were published only in their native
languages [i.e. Dutch (53%; n = 12), and Spanish and Danish
(both 22%; n = 5)]. There were also some inconsistencies in
the keyword nomenclature: only 115% (n = 26) were titled
as ‘clinical practice guidelines’. Furthermore, 885% (n = 200)
of included articles had at least one keyword in the title, most
frequently ‘guideline’ (642%; n = 145), ‘consensus’ (146%;
n = 33) and ‘recommendation’ (97%; n = 22).
Most CPGs focused on treatment/management recommen-
dations (429%; n = 97), while other CPGs were broader in
scope and covered diagnostic/treatment (305%; n = 69) and
diagnostic/treatment/prevention (204%; n = 46) (Figure 4).
Specifically, a significant proportion of CPGs on psoriasis
(106%; n = 24), melanoma (102%; n = 23), atopic and con-
tact dermatitis (75%; n = 17) and acne (22%; n = 5) focused
on drug and treatment recommendations, while CPGs on
venous ulcers (84%; n = 19) and keratinocyte carcinoma
(44%; n = 10) included additional aspects on prevention and
long-term management. There were also drug-/treatment-
specific CPGs (35%; n = 8), for example photodynamic ther-
apy and systemic treatments, which provided recommenda-
tions spanning a range of skin diseases.
Funding source and open access
All 226 guidelines were assessed for inclusion of a funding
statement and accessibility (Table S1; see Supporting Informa-
tion). Approximately 394% (n = 89) of CPGs failed to pro-
vide a funding statement. In CPGs with a funding statement,
dermatology/medical societies were the most common source
(159%; n = 36), followed by government/public funding
(111%; n = 25). Eight per cent (n = 18) of CPGs, including
topics such as acne, atopic and contact dermatitis, ker-
atinocytes carcinomas and psoriasis, declared funding from
pharmaceutical companies. Furthermore, 850% (n = 192) of
CPGs were open access, while many of the CPGs that were
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flowchart illustrating the process for the selection of the
included guidelines for the scoping review. CPG, clinical practice guidelines; GIN, Guidelines International Network; ILDS, International League of
Dermatological Societies; NICE, National Institute for Health and Care Excellence.
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behind a paywall originated from high–middle (13%; n = 3)
and high SDI (133%; n = 30) countries.
Comparison of disability-adjusted life-year outcomes for
specific skin disease clinical practice guidelines
Comparing the total number of CPGs representing skin dis-
eases mapped to the GBD’s DALY estimates, we found that the
coefficient of determination (R2) was 01676, indicating over-
all poor correlation between these variables (Figure 5). Mela-
noma and keratinocyte cancers had disproportionately greater
CPGs representation, compared with its disease burden, as
measured by DALYs, particularly predominance by high-
income countries (e.g. Australasia, Europe and North Amer-
ica). CPG representation of urticaria, atopic and contact der-
matitis appeared to be proportionately aligned with their
DALY metrics. Acne, alopecia areata, cellulitis and scabies were
under-represented in the number of CPGs, compared with
their corresponding DALY metrics.
Discussion
To our knowledge, this is the first scoping review to provide
a comprehensive global overview of the number and charac-
teristics of CPGs for common dermatological conditions. We
define dermatology as the study of diseases affecting the skin,
hair and nails, including venereology and tropical skin dis-
eases, to represent global skin health needs. Our systematic
search, screened by two independent reviewers, found 226
CPGs on skin conditions from October 2014 to October 2019,
with a lack of correlation to the GBD 2019 disease burden.9,10
As a consequence, a number of research gaps that require
future investigation have been found.
Inflammatory skin conditions (e.g. atopic and contact der-
matitis, psoriasis and urticaria) and skin cancers (keratinocyte
carcinomas and melanoma) cause the greatest disease burden
in high-income countries,12,13 and the greatest increase in the
number of CPGs published for these conditions has been
observed in the last 5 years. The sharp rise in treatment-
related CPGs may be partly explained by the availability of
new, effective treatments for these conditions, for example
targeted immunotherapy for psoriasis and melanoma. How-
ever, the treatment landscape for scabies, tinea capitis and viral
skin diseases, which are more prevalent in low-income coun-
tries, remained almost unchanged.12,13 Newer insights into
chronic skin conditions, such as the prevention of venous leg
ulcer recurrence and skin cancer screening, have led to the
incorporation of preventative recommendations into CPGs for
the management of these long-term conditions.
During the search process for this review, we noticed that a
significant number of local CPGs (283%; n = 64) were not
indexed in electronic library databases and only found on
Figure 2 Stacked bar chart showing the trend of clinical practice guidelines (CPGs) produced from October 2014 to October 2019 according to
different skin disease categories.
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websites, rendering them difficult to find for clinicians and
guideline developers.14 In particular, those on society websites
were hard to find (e.g. archived in nonintuitive subsections of
the website). As a result, the website searches relied heavily
on supplementary hand searches, which might hamper repro-
ducibility efforts in a biomedical database.
This review also found a range of terms being used to
describe skin disease in CPGs. Although over half of the iden-
tified guidelines used the term ‘guideline’ in their title, only a
relatively small number were titled as a ‘clinical practice
guideline’. A number of CPGs were expert recommendations
that might not have been intended to be a CPG, even if they
could be interpreted and used as a guideline. This highlights
the need for a more precise definition of what constitutes a
recommendation statement in contrast to a CPG.
There was also an uneven distribution and substantial varia-
tion of skin disease CPGs by geographical region. The high
number of CPGs developed in North American and European
countries may reflect the healthcare environment in which
CPGs were used to evaluate treatment cost-effectiveness, allo-
cation of resources and healthcare priorities.15 Furthermore,
the review showed significant under-representation of CPGs
from Asia (155%; n = 35), South America (49%; n = 11)
and there was no representation from the African continent.
Low-income countries may have fewer resources to develop
and implement locally written CPGs, or research capacity to
explore local context issues.16 To address this gap, they often
adopt or adapt CPGs from high-income countries, especially
where high-quality guidance already exists.17 However, these
CPGs are sometimes written with different health systems in
CPGs (N) High SDI
















































Figure 3 Representation of skin disease clinical practice guidelines (CPGs) according to corresponding countries and their sociodemographic index
(SDI).
Figure 4 Venn diagram showing distribution of topics covered in skin
disease CPGs.
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mind, potentially leading to under-representation of consider-
ations around skin of colour, resource and workforce availabil-
ity. As a result, the guidance in CPGs might not be directly
appropriate for local implementation.16 The generalisability of
CPGs in some skin diseases could also be improved by increas-
ing international collaborations during guideline develop-
ment.2 CPGs produced in collaboration with other countries
were more frequently of higher methodological standards and
conform with the internationally accepted quality criteria.5
Regular monitoring of existing CPGs and timely dissemina-
tion of updated ones are essential ways of ensuring that CPGs
remain useful in improving healthcare quality and patient out-
come.18 For example, the Association of the Scientific Medical
Societies in Germany and NICE in the UK require CPGs to be
checked or updated every 3–5 years. This is particularly impor-
tant in disease areas where there are significant evidence gaps
or where numerous new effective treatments have been intro-
duced. In our hand search, we found a number of skin disease
CPGs, in particular from dermatological societies in low-income
countries, that were updated less regularly than those from
high-income countries and, as they were outside the study
timeframe, were excluded during the screening process.
The process of writing a guideline is time- and resource-
consuming. We propose that further collaboration between
guideline developers on quality assessment could limit the
workload and that sharing of knowledge and expertise might
also increase the overall quality of individual local guidelines.
The concept of ‘living guidelines’ could potentially make this
more feasible, with the promise to provide timely, up-to-date
and high-quality guidance to target users.19 Therefore, our
team has developed a web repository of dermatological CPGs
based on the current work. The open online resource, which
can be found at https://sites.manchester.ac.uk/guidemap/, is
a work in progress and will be updated over time as our team
update the literature search and start to perform critical
appraisal of the collated CPGs.
The source of funding for CPGs may create conflicts of
interest, especially for CPGs involving treatment recommenda-
tions, and may introduce bias in the development of CPGs.
Over one-third of GDGs failed to declare their source of fund-
ing. Approximately 7% of GDGs received financial funding
from the pharmaceutical industry, although most claimed to
have maintained editorial independence. The influence of
industry sponsorship or GDG members’ conflicts of interest
may be particularly important where evidence is lacking or of
poor quality.20 This level of participation can affect readers’
opinions regarding the integrity of these CPGs, and some
studies have even documented that disclosure of industry
funding may lead clinicians to downgrade the quality of the
guideline content.21
A number of CPGs (150%; n = 34) were published behind
paywalls, which restricts access to research findings and limitis
the dissemination and clinical benefit of CPGs to clinicians and
patients. They also exacerbate the substantial inequalities in
Figure 5 Scatter chart comparing the correlation between nine skin disease clinical practice guidelines (CPGs) and the corresponding disability-
adjusted life-years (DALYs) as measured in the 2019 Global Disease Burden (GBD) study. Three of the 12 skin diseases (tinea capitis, viral warts
and molluscum contagiosum, and venous ulcers) were used as representative conditions in the review for which there were no DALY data
available from the GBD study. These three groups were therefore excluded from the correlation analysis.
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scholarly resources between developed and developing coun-
tries, creating a barrier to access important medical knowl-
edge.22
The concept of ‘disease burden’ can be expressed in terms
of DALYs, calculated as the sum of years of life lost plus the
years of productive life lost due to ill health, disability or pre-
mature death. The global burden of skin and subcutaneous
diseases has been steadily increasing (total DALYs from 12%
in 1990 to 18% in 2017).9,23 Our study showed weak associ-
ation between DALYs and the representation of CPGs accord-
ing to their skin disease categories. The findings are consistent
with reports of poor association between global burden of dis-
ease and the number of published randomized trials,24 and
moderate correlation between systematic reviews and DALYs
across the entire Cochrane Database of Systematic Reviews.25
Furthermore, a study in 2015 comparing research funding by
the US National Institutes of Health demonstrated that skin
cancer research was generally overfunded, whereas dermatitis,
decubitus ulcer, fungal skin diseases and cellulitis received
substantially less financial support.15 Although skin cancers are
represented by lower DALYs according to GBD metrics, their
true burden is thought to be significantly underestimated, and
thus might still be deemed important because of the associated
morbidity and mortality. We recognize that many variables
play a part in research prioritization and development of
CPGs, including disease prevalence, therapeutic options, geo-
graphical and clinical settings, cost constraints and local
resource availability, healthcare priority setting, pharmaceutical
suppliers and public interest.26,27
Our systematic search strategy aimed to identify all available
skin diseases CPGs from October 2014 to October 2019.
However, some guidelines have a built-in ‘expiry date’ and
are renewed according to a fixed schedule. We cannot exclude
that some relevant CPGs may have fallen beyond the search
scope and time limits of this review. We may also have
missed CPGs that are inaccessible to the public, and some der-
matological societies did not respond to us contacting them
about accessing their CPGs. If a CPG did not clearly identify
itself as a guideline, or if the meaning was lost during transla-
tion of a non-English CPG, it might have been missed in this
review, despite measures taken to limit such omissions. In
addition, we did not formally assess the quality of individual
CPGs with a validated tool, as this will be the focus of future
work.
In this first global scoping collation of CPGs for common
dermatological conditions, we found numerous internationally
available CPGs for the diagnosis, treatment and prevention of
these diseases. By highlighting the current state and numbers
of CPGs in dermatology, we provide insight into the potential
mismatch between the resources used to develop CPGs for cer-
tain dermatological diseases and the corresponding disease
burden worldwide. For the next stage of this project, we will
perform critical appraisal to assess the quality of each of the
included CPG, with the overarching objective to establish an
accessible online resource indexing current and future CPGs in
dermatology ranked by guideline quality.
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